Aligos Therapeutics, Inc. ALGS
4.75 USD +0.15 (+3.26%)
At closeNov 3, 2026, 4:02 PM EST
4.75 0.00 0.00%
After hours · Nov 3, 4:02 PM ET
4.65 Day range 4.95
3.98 52-week range 13.69
- YTD
- -49.03%
- 1 year
- -36.92%
Financial health
Altman Z-Score
-16.11 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 3
- P/E 1
- P/B 3
Valuation
P/E -3.8×
FY 2018 5y median -4.7× FY 2025
P/S 42.1×
FY 2018 5y median 63.3× FY 2025
P/B 1.7×
FY 2018 5y median 4.5× FY 2025
P/FCF -1.1×
FY 2018 5y median -5.2× FY 2025
EV/EBITDA -3.4×
FY 2018 5y median -3.4× FY 2025
EV/Sales 36.2×
FY 2018 5y median 56.0× FY 2025
FCF Yield -90.0%
FY 2018 5y median -19.1% FY 2025
Profitability
Gross Margin 57.5%
FY 2018 5y median 100.0% FY 2025
Operating Margin -4024.9%
FY 2018 5y median -2259.9% FY 2025
Net Margin -1106.7%
FY 2018 5y median -1106.7% FY 2025
ROE -45.2%
FY 2018 5y median -69.5% FY 2025
ROIC -123.9%
FY 2018 5y median -83.6% FY 2025
ROA -27.3%
FY 2018 5y median -57.9% FY 2025
Growth (YoY)
Revenue -44.6%
FY 2018 FY 2025
Operating Income 1.3%
FY 2018 FY 2025
EPS (diluted) 88.3%
FY 2018 FY 2025
Free Cash Flow -2.6%
FY 2018 FY 2025
Financial Health
Current Ratio 3.9×
FY 2018 5y median 4.0× FY 2025
Quick Ratio 3.9×
FY 2018 5y median 4.0× FY 2025
Debt / Equity 0.1×
FY 2018 5y median 0.1× FY 2025
Net Debt / EBITDA 0.6×
FY 2018 5y median 0.7× FY 2025
Interest Coverage 0.0×
FY 2018 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2018 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2018 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31
